Background: Urinary tract infections are a very common type of infection in the urinary system. It's more common in female, Elderly, recent catheterization and Sexual Activity. The disease can involve any part of your urinary system from a relatively benign cystitis to potentially life-threatening pyelonephritis. They are the most common infection among elderly population and the most common cause of hospitalization. The diagnosis and treatment of urinary tract infections in elderly people is considered difficult due to certain risk factors include diabetes mellitus, aging, impaired immunity, spinal cord injuries and the use of urinary catheters. Methods: A retrospective observational study was conducted between January 2020 and December 2024. A total of 350 elderly patients (≥65 years) diagnosed with urinary tract infections were included. Data were extracted from electronic medical records, including sociodemographic characteristics, comorbidities, medication regimens, and treatment outcomes. Descriptive statistics were used to summarize data, and logistic regression was performed to identify predictors of poor treatment outcomes. Results: Among the study population, 63.5% had complicated urinary tract infections, with hypertension (62.4%) and diabetes mellitus (48.2%) being the most common comorbidities. Polypharmacy (≥5 medications) was present in 63.5% of patients, and 14.1% were on ≥10 medications. Nitrofurantoin (32.9%) and ciprofloxacin (25.9%) were the most commonly prescribed antibiotics. Older age (≥85 years, OR=2.5, p<0.001) diabetes mellitus (OR=1.9, p<0.001), chronic kidney disease (OR=2.2, p<0.001), urinary catheterization history (OR=2.8, p<0.001), and polypharmacy (OR=1.7, p=0.002) were significant predictors of poor treatment outcomes. Conclusion: Elderly patients with urinary tract infections frequently present with multiple comorbidities and high medication burdens, complicating treatment and increasing the risk of adverse outcomes. Polypharmacy and chronic conditions such as diabetes and chronic kidney disease significantly impact treatment success. Improved antibiotic stewardship and individualized treatment strategies are needed to optimize outcomes in this vulnerable population.
Saudi Journal of Biological Sciences · مجلد 29 (5) · 3326-3337
COVID-19 (coronavirus disease-2019) is a contagious illness that has been declared a global epidemic by the World Health Organization (WHO). The coronavirus causes diseases ranging in severity from the common cold to severe respiratory diseases and death. Coronavirus primarily affects blood pressure by attaching to the angiotensin converting enzyme 2 (ACE 2) receptor. This virus has an impact on multiple organ systems, including the central nervous system, immune system, cardiovascular system, peripheral nervous system, gastrointestinal tract, endocrine system, urinary system, skin, and pregnancy. For the prevention of COVID-19, various vaccines such as viral-like particle vaccines, entire inactivated virus vaccines, viral vector vaccines, live attenuated virus vaccines, subunit vaccines, RNA vaccines, and DNA vaccines are now available. Some of the COVID-19 vaccines are reported to cause a variety of adverse effects that range from mild to severe in nature. SARS-CoV-2 replication is controlled by the RNA-Dependent RNA-Polymerase enzyme (RdRp). The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection. RdRp inhibitors, such as remdesivir (an anti-Ebola virus experimental drug) and favipiravir (an anti-influenza drug), inhibit RdRp and thus slow the progression of COVID-19 and associated clinical symptoms, as well as significantly shorten recovery time. Molnupiravir, an orally active RdRp inhibitor and noval broad spectrum antiviral agent, is an isopropyl pro-drug of EIDD-1931 for emergency use. Galidesivir's in vitro and in vivo activities are limited to RNA of human public health concern. Top seeds for antiviral treatments with high potential to combat the SARS-CoV-2 strain include guanosine derivatives (IDX-184), setrobuvir, and YAK. The goal of this review is to compile scattered information on available COVID-19 vaccines and other treatments for protecting the human body from their harmful effects and to provide options for making better choices in a timely manner.